Cochrane · systematic review · CD010458
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
Rodrigo, C, Rajapakse, S, Fernando, D · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 33.3%Low 0 · 0%Moderate 4 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings table 1
Population: adults with P vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P vivax parasitaemia during 6 months of | RR 0.32 [0.12, 0.88] | 2 studies · 504 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events | RR 1.34 [0.63, 2.84] | 2 studies · 504 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Any adverse event | RR 0.96 [0.81, 1.13] | 2 studies · 504 participants | Moderate Downgraded: risk of bias, indirectness |
Summary of findings table 2
Population: adults and children with P vivax malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
P vivax parasitaemia during 6 months of | 1.04 [0.8, 1.34] | 3 studies · 747 participants | Moderate Downgraded: risk of bias, inconsistency, indirectness |
Serious adverse events | RR 1.41 [0.7, 2.83] | 3 studies · 747 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Any adverse event | RR 1.01 [0.89, 1.14] | 3 studies · 747 participants | Moderate Downgraded: risk of bias, indirectness |